All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-10-31T09:58:32.000Z

ESH 2019 | What's new in flow cytometry assessment of MRD?

By Jacqueline Cloos
Featured
Jacqueline Cloos
Oct 31, 2019
Share:

Bookmark this article

The AML Global Portal were delighted to speak to Jacqueline Cloos, VU University Medical Center, Amsterdam, NL, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Jacqueline Cloos: What's new in flow cytometry assessment of MRD? She discusses how clinically validated MRD can be improved to act as a surrogate end-point in clinical trials.

What's new in flow cytometry assessment of MRD?

More about...
De novoDiseaseESH 2019Secondary

Related articles

Add bookmark

HMA + venetoclax may improve outcomes in patients with splicing mutations

Spliceosome mutations, including SRSF2, U2AF1, SF3B1, and ZRSR2, are identified in approximately one-third of patients with myelodysplastic syndromes (MDS) and in almost 50% of...

Jun 15, 2021
Add bookmark

HMA + venetoclax may improve outcomes in patients with splicing mutations

Spliceosome mutations, including SRSF2, U2AF1, SF3B1, and ZRSR2, are identified in approximately one-third of patients with...

Jun 15, 2021
Add bookmark

ESH 2019 | What is the risk of developing AML in women previously treated for breast cancer?

Norbert Vey, Institut Paoli-Calmettes, Marseille, FR, during the European School of Hematology (ESH) Translational Research Conference on AML.

Oct 31, 2019
Add bookmark

ESH 2019 | What is the risk of developing AML in women previously treated for breast cancer?

Norbert Vey, Institut Paoli-Calmettes, Marseille, FR, during the European School of Hematology (ESH)...

Oct 31, 2019

Newsletter

Subscribe to get the best content related to AML delivered to your inbox